STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

CBAY CYMABAY THERAPEUTICS INCORPORATED StockScouter® Report

5

StockScouter® Score

CYMABAY THERAPEUTICS INCORPORATED, a mid cap company in the healthcare sector, is expected to perform in line with the market over the next six months with average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • Earnings growth in the past year has accelerated moderately compared to earnings growth in the past three years. Positive
  • The multi-period measure of relative price change and consistency is well above average. Positive

 

Concerns

  • The most recent quarterly earnings report was significantly lower than analysts’ consensus forecast. Negative
  • The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that mid cap stocks will be neutral, stocks will be , and healthcare stocks will be neutral.

Expected Risk/Return

Progress: 60% done.
Progress: 60% done.
Low
High

Core Model Grades

C
D
F
A

Previous Ratings

3
5
5